Physician profile
Michael J Walker
NPI 1871538611
$65,044.40
in general payments reported to CMS, 2019-2025
24 companies · $934 in 2025
The $934 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $18K · 2021: $7,052 · 2022: $6,986 · 2023: $4,103 · 2024: $1,465 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250 · Food and Beverage: $2,727 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
| Food and Beverage | $2,726.77 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56,047.24 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Medtronic, INC. | $4,711.72 | 2021-2025 | Signia, Ligasure, Signet |
| E.R. Squibb & Sons, L.L.C. | $2,083.68 | 2019-2022 | |
| Ethicon US, LLC | $300.00 | 2019 | |
| Baxter Healthcare | $219.46 | 2019-2023 | Tisseel |
| Atricure, INC. | $199.30 | 2023-2024 | |
| Boston Scientific Corporation | $188.78 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $188.28 | 2023-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $126.00 | 2024-2025 | |
| Celgene Corporation | $124.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $115.13 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $106.12 | 2019-2025 | Tecentriq, Tecentriq Hybreza |
| Mirati Therapeutics, INC. | $96.69 | 2023-2024 | Krazati |
| Incyte Corporation | $76.95 | 2024-2025 | Monjuvi, Jakafi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $70.44 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $65.62 | 2024-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $63.55 | 2019-2020 | |
| Caris Mpi, INC. | $52.11 | 2025 | Mi Cancer Seek |
| Sobi, INC | $49.93 | 2024-2025 | |
| Janssen Biotech, INC. | $47.35 | 2024-2025 | Rybrevant |
| Eisai INC. | $46.91 | 2024-2025 | |
| Foundation Medicine, INC. | $30.79 | 2019-2020 | |
| Lemaitre Vascular, INC. | $18.42 | 2019 | |
| Solventum Corporation | $15.91 | 2025 | Prevena, V.A.C.Ulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.